All these premeses lead to the hypothesis that targeting the RANK/RANKL pathway with denosumab, an already available, clinically approved monoclonal antibody for metastatic bone lesions, might restore proper anti-tumor immune response in NPC metastatic patients. The gene discussed is TNFSF11; the disease is neoplasm.